This study is in progress, not accepting new patients
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Summary
- Eligibility
- for people ages 18-85 (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Intercept Pharmaceuticals
- ID
- NCT02548351
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 2480 people participating
- Last Updated